Renalys Pharma

Renalys Pharma is a privately-held, late-stage clinical biopharmaceutical company headquartered in Japan, dedicated to developing a range of innovative therapies to address the unmet needs of patients with kidney diseases in Japan and across Asia. Founded in 2023 by Catalys Pacific and SR One, the company aims to tackle the growing issue of "drug lag" by facilitating access to new treatments for patients with kidney diseases in Japan and other Asian regions.